News

Biogen Presents Update on its MS Therapeutic Portfolio

Biogen has released new data on several of its therapies for multiple sclerosis (MS), including Vumerity (diroximel fumarate), Tecfidera (dimethyl fumarate), and Tysabri (natalizumab). The data — six presentations — originally were to be presented at the 2020 annual conference of the American…

MS Patients Have More Aluminum Content in Their Brains Than Those Without Neurodegenerative Conditions, Study Finds

People with multiple sclerosis (MS) and other neurological diseases have a significantly higher aluminum content in their brains than those with no known neurological impairment and no identifiable neurodegenerative disease, a recent study found. The research further supports a role of aluminum in the development of these brain conditions,…

Progressive MS Linked to Faster Retinal Atrophy, Study Shows

People with progressive forms of multiple sclerosis (MS) have faster and disease-modifying therapy (DMT)-resistant retinal atrophy (thinning), compared to those with relapsing-remitting MS (RRMS), a study shows. Data also highlighted that the thickness of deeper layers of the retina could be used as potential biomarkers of neurodegeneration in…

NurOwn May Curb Damaging Neuroinflammation in MS, Study Finds

NurOwn, believed to have neuroprotective and repairing effects, may also be able to curb the damaging immune responses that contribute to multiple sclerosis (MS) progression, a recent study found. This newly identified potential may extend the benefits of this cell-based therapy, its researchers believe. The findings were to be presented…

MS Society of Canada Launches Virtual Fundraising Campaign

The Multiple Sclerosis Society of Canada is launching a virtual effort that seeks to connect multiple sclerosis (MS) communities across the country and raise funds for research in observance of Multiple Sclerosis Awareness Month in Canada. As part of the initiative, called #WeChallengeMS, Canadian…